Table 3

Monoallelic variants in genes associated with autosomal recessive PIDs as well as in CLEC16A and TNFRSF13B, identified in patients with rheumatic diseases with persistent hypogammaglobulinaemia and those without

Pat.
ID
AgeSexRheumatic diseaseGeneRef. seq. transcriptCoding changeProtein changegnomAD allele freq.RS-IDCADD scoreMSC–CADD scorePolyPhen2 scorePolyPhen2 pred.SIFT scoreSIFT pred.
A: Patients with persistent hypogammaglobulinaemia
157FSpA RAG1 NM_000448.ex.2c.1346G>Ap.R449KRS415103118.7201.1180.900Possibly damaging0.190T
258FSpA CD79A NM_001783.ex.2c.371G>Ap.R124H0.0009118033.00022.9000.984Probably damagingNANA
363FSpA TCF3 NM_001136139.ex.9c.709G>Tp.G237W32.0003.3130.986Probably damaging0.000D
651FRA RAD50 NM_005732.ex.23c.3596G>Tp.G1199V32.0000.0011.000Possibly damaging0.000D
NBN NM_001024688.ex.4c.37G>Ap.D13N0.001858RS6175372026.3000.0031.000Probably damaging0.030D
1080FGPA CLEC16A NM_001243403.ex.21c.2572C>Ap.Q840K22.1003.3130.318Benign0.000D
1453FRA TCF3 NM_001136139.ex.5c.302A>Gp.K101RRS4127584218.4003.3130.052Benign0.040D
1659MPAN CLEC16A NM_015226.ex.22c.2675G>Ap.S892NRS7265068719.6803.3130.001Benign0.000D
RAG1 NM_000448.ex.2c.1537C>Ap.L513I25.6001.1180.991Probably damaging0.000D
1968FRA ADA NM_000022.ex.8c.700G>Tp.E234*40.00011.150NANA0.010D
NBN NM_001024688.ex.10c.1077C>Ap.N277K19.5700.0030.576Possibly damaging0.010D
2066FSjS TNFRSF13B NM_012452.ex.4c.542C>Ap.A181E0.005360rs7255388322.8000.0270.395Benign0.050D
2164MSLE TGFB1 NM_000660.ex.5c.832C>Tp.R278*36.0006.330NANA1.000T
2253FRA STIM1 NM_003156.ex.12c.1928G>Ap.R643H0.00097200RS14008019929.90014.1100.980Probably damaging0.000D
2669FRA NBN NM_001024688.ex.12c.1840_1840delAI614Yfs*4323.7000.003NANANANA
2852MRA RAG1 NM_000448.ex.2c.2824A>Cp.T942P23.2001.1180.997Probably damagingNANA
2953FRA CLEC16A NM_001243403.ex.21c.2430C>Ap.D810E0.00002000RS20090837323.9003.3130.292Benign0.000D
TNFRSF13B NM_012452.ex.4c.542C>Ap.A181E0.005360RS7255388322.8000.0270.395Benign0.050D
3069FRA BLNK NM_001114094.ex.2c.88G>Ap.G30R0.0007476RS14310914432.0003.3130.973Probably damaging0.200T
3158FSLE RAD50 NM_005732.ex.16c.2548C>Tp.R850C0.00028850RS18196136035.0000.0010.724Possibly damaging0.050D
3262FSLE RELB NM_006509.ex.1c.56C>Gp.P19R24.5003.3130.993Probably damaging0.000D
TNFRSF13B NM_012452.ex.2c.198C>Ap.C66*0.000008258RS14471800736.0000.027NANA1.000T
4172FSLE IGLL1 NM_020070.ex.3c.421_421delTY141Ifs*50.000337824.2003.313NANANANA
4347FSpA TCF3 NM_001136139.ex.5c.302A>Gp.K101R0.00964RS4127584218.4003.3130.052Benign0.040D
5161FSjS CD81 IVS5-124.40012.063NANANANA
5628MSLE TGFB1 NM_000660.ex.3c.593T>Cp.F198S32.0006.3301.000Probably damaging0.000D
5840FRA RAG1 NM_000448.ex.2c.1346G>Ap.R449K0.003618.7201.1180.900Possibly damaging0.190T
6260FSjS CD79A NM_021601.ex.5c.499G>T p.G167C22.90022.900NAPossibly damaging0.239NA
6374MSLE TGFB1 NM_000660.ex.7c.1147A>Tp.I383F28.2006.3300.000Possibly damaging0.027D
B: Patients without hypogammaglobulinaemia
6573FSjS RLTPR NM_001013838.ex.20c.1783_1783delAp.K595Sfs*110.00000838134.0003.313NANANANA
7248FSLE RLTPR NM_001317026.ex.36c.3914G>Tp.G1305V23.5003.3130.767Possibly damaging0.030D
8452FSLE NBN NM_152309.ex.2c.84G>Tp.R28S29.0000.0031.000Probably damaging0.000D
8533FSLE NBN NM_002485.ex.2c.79G>Tp.G27*38.0000.003NANA0.000D
8951FSLE CLEC16A NM_001243403.ex.21c.2524C>Tp.R842C0.0002983RS19951322935.0003.3130.997Probably damaging0.000D
12052FSjS CR2 NM_001877.ex.14c.2659G>Ap.V887M0.0003997RS14745132425.6003.8320.951Probably damaging0.100T
  • *substitution - nonsense.

  • .*, substitution-nonsense; AR, autosomal recessive; CADD, Combined Annotation Dependent Depletion; D, damaging; F, female; freq., frequency; gnomAD, Genome Aggregation Database; GPA, granulomatosis with polyangiitis; Pat. ID, patient identification number; M, male; MSC, Mutation Significance Cut-off; NA, not applicable; PAN, polyarteritis nodosa; PIDs, primary immunodeficiency disorders; PolyPhen2, Polymorphism Phenotyping v2; pred., prediction; RA, rheumatoid arthritis; ref. seq., reference sequence; SIFT, Sorting Intolerance From Tolerance; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; T, tolerated.